TOVX
Theriva Biologics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 12 Theriva Biologics reported financial results for 2025 and provided c…
- Mar 12 Theriva Biologics reported its 2025 financial results, highlighted b…
- Mar 31 ▲ Maxim Group upgrades
- Apr 17 ▲ Theriva Biologics announced positive results from its VIRAGE Phase 2…
- Jun 11 ▲ Theriva Biologics announced publication of Phase 1 trial results for…
- Jun 11 FDA: Theriva™ Biologics Announces Results from VCN-01 Phase 1 C…
- Nov 12 ▲ Earnings: TOVX Q3 2026 Earnings: EPS $-0.03 (+51.0% vs est)
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q3 2026: 1 added (0 new), 2 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate −$0.050 → −$0.060 over 90 days. 0 up, 1 down in 30 days.
- Short sellersCOVERING
Short interest −23.4% to 1.41M shares. 2.7 days to cover, ≈3.1% of shares.
- TrendDOWNTREND
32% below its 50-day average. New closing low $0.1400 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JANE STREET GROUP, LLC | TRIM | $36.2K |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $24.6K |
| UBS Group AG | NEAR_EXIT | $3.1K |
| VANGUARD CAPITAL MANAGEMENT LLC | DOUBLED | $121.5K |
| JANE STREET GROUP, LLC | ADD | $83.0K |
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | $73.6K |
| UBS Group AG | TRIM | $15.3K |
| OSAIC HOLDINGS, INC. | DOUBLED | $110.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Mar 2026Price is below the lowest target. Median implies +2757%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Mar 31, 2026 | Maxim Group UPGRADE | Buy |
| May 8, 2025 | Maxim Group DOWNGRADE | Hold |
| Nov 13, 2024 | Maxim Group MAINTAIN | Buy |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.06 | -$0.06–-$0.06 | -20.0% | $0.00 |
| Next Q | -$0.05 | -$0.05–-$0.05 | No data | $0.00 |
| Current FY | -$0.25 | -$0.25–-$0.25 | -25.0% | $300.0K |
| Next FY | -$0.20 | -$0.20–-$0.20 | +0.0% | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
9 filings · 2 press releases · 2 bullish · 2 bearish · 1 mixed · 4 neutral- NEUTRAL PRESS-RELEASENov 12, 2026
Theriva Biologics reported Q3 2026 net loss of $1.47M ($0.03 per share), narrower than the $4.36M…
Cash runway into Q1 2027 is very short for a clinical-stage company; monitor for financing or partnership announcements. VIRAGE2 enrollment completion and initial data in Q3 2027 are the next key…
- NEUTRAL 8-KNov 2, 2026
Theriva Biologics sold its SYN-004 (ribaxamase), SYN-007, and SYN-006 antibiotic-degrading enzyme…
The sale provides immediate cash but removes a pipeline asset; Theriva now focuses on its oncolytic adenovirus platform (VCN-01). Monitor Biossil's progress in advancing the Phase 1b/2a trial for…
- BEARISH DEF 14AOct 20, 2026
Theriva Biologics is holding a special meeting on November 18, 2026, to seek stockholder approval…
Monitor the special meeting vote outcome on November 18. If the warrant exercise proposal fails, the company faces litigation risk and loss of ~$8.7M potential proceeds. If the authorized share…
- NEUTRAL 8-KAug 11, 2026
Theriva Biologics reported Q2 2026 financial results with a net loss of $3.2M ($0.07/share)…
This is a routine quarterly update for a pre-revenue clinical-stage biotech with no material financial surprises. The VIRAGE2 dosing and retinoblastoma protocol design are incremental pipeline…
All TOVX filing & press-release reports (11)
- PRESS-RELEASE reportNov 12, 2026
- 8-K reportNov 2, 2026
- DEF 14A reportOct 20, 2026
- 8-K reportAug 11, 2026
- PRESS-RELEASE reportAug 11, 2026
- 8-K reportAug 4, 2026
- 8-K reportJul 7, 2026
- PRESS-RELEASE reportJun 11, 2026
- 8-K reportApr 17, 2026
- 8-K reportMar 12, 2026
- PRESS-RELEASE reportMar 12, 2026